TD Cowen Says Novartis (NVS) Has Strong Growth Path Through 2029

Novartis AG (NYSE:NVS) ranks among the best slow growth stocks to invest in. Following meetings with Novartis AG (NYSE:NVS)’s head of U.S. operations in Boston, New York, and San Francisco, TD Cowen reaffirmed its Hold rating on the company’s shares on November 10 with a price target of $140. The meetings revealed a number of growth drivers that support Novartis’ estimated 6% sales CAGR from 2024 to 2029. lucarista/Shutterstock.com Existing medicines like Cosentyx, Pluvicto, Kisqali, Leqvio, Kesimpta, a ...